Kim Haekyu, Kim Hyae Jin, Jung Young-Hoon, Do Wangseok, Kim Eun-Jung
Department of Anesthesia and Pain Medicine, School of Medicine, Pusan National University, Busan, Republic of Korea.
Department of Anesthesia and Pain Medicine, Biomedical research institute, Pusan National University Hospital, Busan, Republic of Korea.
J Dent Anesth Pain Med. 2024 Feb;24(1):47-56. doi: 10.17245/jdapm.2024.24.1.47. Epub 2024 Feb 1.
Among the various pain-related diseases that can be encountered at the clinic, there is a neuropathic pain that is difficult to treat. Numerous methods have been proposed to treat neuropathic pain, such as taking medication, nerve block with lidocaine, or neurolysis with alcohol or phenol. Recently, a method of perineural injection using dextrose instead of lidocaine was proposed. This study was designed to compare the effects of perineural injection therapy (PIT) with buffered 5% dextrose or 0.5% lidocaine on neuropathic pain.
The data were collected from the database of pain clinic from August 1st, 2019 to December 31st, 2022 without any personal information. The inclusion criteria were patients diagnosed with postherpetic neuralgia (PHN), trigeminal neuralgia (TN), complex regional pain syndrome (CRPS), or peripheral neuropathy (PN), and patients who had undergone PIT with buffered 5% dextrose (Dextrose group) or 0.5% lidocaine (Lidocaine group) for pain control. The data of patients, namely sex, age, and pain score (numerical rating scale, NRS) were collected before PIT. The data of NRS, side effects, and satisfaction grade (excellent, good, fair, or poor) were collected one week after each of the four PIT, and two weeks after the last PIT.
Overall, 112 subjects were enrolled. The Dextrose group included 89 and Lidocaine group included 23 patients. Because the number of patients in the Lidocaine group was too small to allow statistical analysis, the trend in Lidocaine group was just observed in each disease. There were no significant side effects except for a few bruise cases on the site of injection in all groups. The NRS in most Dextrose groups except CRPS were reduced significantly; however, the Lidocaine group showed a trend of pain reduction only in PHN. The Dextrose group except CRPS showed increased satisfaction two weeks after the final PIT.
From the results, it is suggested that PIT with buffered 5% dextrose may have a good effect for neuropathic pain without any side effect except for patients with CRPS. This may offer a window into a new tool that practitioners can employ in their quest to help patients with neuropathic pain.
在临床上可能遇到的各种与疼痛相关的疾病中,有一种神经性疼痛难以治疗。已经提出了许多治疗神经性疼痛的方法,如服药、用利多卡因进行神经阻滞或用酒精或苯酚进行神经溶解。最近,有人提出了一种用葡萄糖代替利多卡因进行神经周围注射的方法。本研究旨在比较用缓冲5%葡萄糖或0.5%利多卡因进行神经周围注射治疗(PIT)对神经性疼痛的效果。
数据收集自2019年8月1日至2022年12月31日疼痛诊所的数据库,不包含任何个人信息。纳入标准为诊断为带状疱疹后神经痛(PHN)、三叉神经痛(TN)、复杂性区域疼痛综合征(CRPS)或周围神经病变(PN)的患者,以及为控制疼痛而接受过用缓冲5%葡萄糖(葡萄糖组)或0.5%利多卡因(利多卡因组)进行PIT的患者。在PIT前收集患者的数据,即性别、年龄和疼痛评分(数字评定量表,NRS)。在四次PIT每次之后一周以及最后一次PIT之后两周收集NRS、副作用和满意度等级(优秀、良好、中等或差)的数据。
总体而言,共纳入112名受试者。葡萄糖组包括89名患者,利多卡因组包括23名患者。由于利多卡因组患者数量太少,无法进行统计分析,因此仅观察了利多卡因组在每种疾病中的趋势。除了所有组中注射部位有少数瘀伤病例外,没有明显的副作用。除CRPS外,大多数葡萄糖组的NRS显著降低;然而,利多卡因组仅在PHN中显示出疼痛减轻的趋势。除CRPS外,葡萄糖组在最后一次PIT后两周显示满意度提高。
从结果来看,提示用缓冲5%葡萄糖进行PIT对神经性疼痛可能有良好效果,除CRPS患者外无任何副作用。这可能为从业者在帮助神经性疼痛患者的探索中提供一种新工具。